FWIW Australian biotechs always limp through clinical trials being very conservative of cash outlay & trying to do everything as cheaply as possible. Big Pharma & Big Biotech completely different paradigm they spare no expense and drop multiples of what would generally be considered sufficient funds. Hence why any kind of split funding for trials would really not work favourably.
running out of ammo?, page-61
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(12.5%) |
Mkt cap ! $7.201M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $564 | 161.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 39 | 29348732 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 26555626 | 17 |
View Market Depth
| Last trade - 12.59pm 18/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |